35 results about "Antigen response" patented technology

The application discloses methods for simultaneous detection and quantifying multiple target analytes, including immunoglobulin isotypes and sub-classes, single and multiple protein antibodies within a test sample in a single reaction vessel. The method uses reaction wells as on a multi-well plate, each single well comprising microarrays of: calibration spots, having a predetermined quantity of a target analyte; and capture spots, having multiple agent antibodies, including isotypes and subclasses that specifically bind the target analytes. The captured analytes and the calibration spots are detected with fluorescently labeled antibodies specific for each analyte. The application also discloses methods for detecting and quantifying biomarkers, therapeutic proteins and patient derived antibodies; the use of secondary reagents to determine immunoglobulin classes Ig G, A, M, E and sub-classes including IgG1, IgG2, IgG3, IgG4 and IgA. The intensity of each fluorescent signal allows measurement of a specific immune response to a therapeutic protein and associated analytes.

The invention relates to a kit for detecting urine transferrin through a chemiluminescence enzyme immunoassay method, and a preparation method thereof. The kit comprises an antibody-coated plate, a urine transferrin enzyme antibody, a coating buffer solution, a blocking solution, a urine transferrin standard substance, a standard substance dilution solution, a washing solution, a sample dilution solution and a chemiluminescent substrate solution. According to the present invention, the kit can detect the UTF concentration level of human based on chemiluminescence enzyme immunoassay; the chemiluminescent substrate catalytic enzyme HRP and the anti-UTF antibody are conjugated, the obtained conjugate reacts with the sample or the antigen to form the immune complexes, the chemiluminescent substrate solution is added, the relative light unit of the chemiluminescent reaction is measured, the UTF antigen content in the standard substance/the sample is proportional to the relative light unit measured by the optical system, and through standard curve fitting, the UTF content in the urine sample is determined; and the kit of the invention has advantages of high sensitivity, strong specificity, easy operation, low cost and the like.

The invention relates to the enzyme combined immune absorbing testing for diagnosing bird flu affected chicks. It expands H9N2 bird flu virus, acquiring target section to connect with the carrier to restructure the expressing particle, injecting into bacillus coli expression to get a conjugated protein which is purified to get H9N2 bird flu virus NS1 protein to be antibody wrapping enzyme reaction plate, to build the antibody level to be reacted to inspect of the serum, getting the marginal value and least sample number of the enzyme combined immune adhesive test through statistics, and finally based on the average OD value to identify the bird flu affection status of the overall poultry. Through overall diagnosis, it alleviates nonspecific reaction, provides scientific proof for timely diagnosis and prevention of bird flu.

This disclosure relates to methods for detecting the potency of a drug preparation and/or detecting antibodies in a host reactive against one or more antigens.

The invention relates to the technical field of biopsy of intracellular carbohydrate chain antigen, specifically to a two-photon fluorescent probe, a fluorescence-labeled kit and a detection method used for biopsy of intracellular carbohydrate chain antigen. According to the invention, a two-photon fluorescence labeled antibody LP-IgG and a nitrocellulose-membrane-coated solid-phase antibody Ab are used; during detection, the solid-phase antibody specifically captures to-be-detected antigen through antigen reaction, so an immune complex Ab-Ag is formed; and the two-photon fluorescence labeled antibody LP-IgG is added and fully reacts with the immune complex (LP-IgG.Ab.Ag), then non-specific substances are washed and removed, and results can be detected and determined. The detection method provided by the invention overcomes the disadvantages of poor sensitivity and stability and complicated operation steps in a traditional detection method for carbohydrate antigen; meanwhile, detection samples are no longer limited to blood and peripheral blood, and any sample with carbohydrate chain antigen can be detected by using the kit prepared from the two-photon fluorescence-labeled probe LP.

The invention provides a method of obtaining a population of antigen-specific T cells from peripheral blood of a host. An embodiment of the method of the invention comprises (i) dividing PBMCs from peripheral blood of a host into more than one sub-population; (ii) contacting the PBMCs with an antigen and IL-2; (iii) obtaining a sample of PBMCs from each sub-population; (iv) identifying an antigen-reactive sub-population by determining by high throughput quantitative PCR the expression of a factor produced by the PBMCs of each sample; (v) dividing the antigen-reactive sub-population into microcultures; (vi) identifying the antigen-reactive microculture; and (vii) expanding the microculture, thereby obtaining a population of T cells specific for the antigen. The invention also provides a population of T cells obtained by the inventive method, a pharmaceutical composition comprising the same, and a method of treating a disease in a host using the pharmaceutical composition. Related isolating and screening methods are further provided.

Described is an autologous primary immune cell assay in which an individual's own blood cells may be functionally screened against individual antigens, e.g., T cell epitopes, of interest simultaneously without HLA haplotype-specific reagent. Antigen reactivities are linked to individual T cells using an oligonucleotide-tagging hashing tracking system, which is later deconvolved by single cell sequencing.

The invention discloses a method for enhancing the antigen response of dendrite cells (DC) through inhibiting the DC and the expression of invariant chain protein (li) in modified DC.

The invention discloses immunochromatography test paper and a preparation method and application thereof, and relates to the technical field of immunochromatography detection.The immunochromatography test paper is characterized in that streptavidin is used for conducting detection line membrane scratching, and biotinylated antibodies are transferred to a combination pad, so that double-antibody sandwich reaction of antigens and antibodies starts from the combination pad, the reaction time is prolonged, and the reaction efficiency is improved; the biotinylated antibody can flow on the nitrocellulose membrane, and the reaction capacity with the antigen is higher than that of the antibody fixed on the detection line, so that the production efficiency of the double-antibody sandwich compound is improved, and the sensitivity is improved. Meanwhile, a capture reaction on the nitrocellulose membrane is converted from an antigen-antibody reaction to a streptavidin-biotin reaction, the reaction efficiency is improved by 3-4 orders of magnitude, and the capture efficiency of a detection line on the membrane is improved, so that the detection sensitivity is improved.

Described are methods for simultaneous detection and quantifying multiple target analytes, including immunoglobulin isotypes and sub-classes, single and multiple protein antibodies within a test sample contained in a single reaction vessel. Such methods use reaction wells as on a multi-well plate, each single well comprising microarrays of calibration spots, each having a predetermined quantity of a target analyte; and capture spots, each having multiple agent antibodies, including isotypes and subclasses that specifically bind the target analytes. The captured analytes and the calibration spots are detected with fluorescently labeled antibodies specific for each different target analyte. Calibration spots generate calibration curves for quantitative determinations of different target analytes. Also described are methods for detecting and quantifying biomarkers, therapeutic proteins and patient derived antibodies; the use of secondary reagents to determine immunoglobulin classes Ig G, A, M, E and sub-classes including IgG1, IgG2, IgG3, IgG4 and IgA. The intensity of each fluorescent signal allows measurement of a specific immune response to a therapeutic protein and associated analytes; interrogates neutralizing effects of patient antibodies on therapeutic proteins, e.g., insulin therapy.

The invention discloses a preparation method and application of an antigen reactive T cell based on an RNA vaccine. The preparation method comprises the following steps of constructing an in-vitro expression vector, and carrying out plasmid linearization, in-vitro transcription and purification to obtain the RNA vaccine; obtaining a T cell and a DC cell modified by the RNA vaccine based on a collected PBMC; and carrying out multiplication culture on the DC cell modified by the RNA vaccine and the T cell to obtain the antigen reactive T cell based on the RNA vaccine. According to the preparation method and application of the antigen reactive T cell based on the RNA vaccine, pcDNA3.1 + plasmids are used for constructing the mammal in-vitro expression vector, and compared with traditional polypeptide synthesis, the preparation period is short, the cost is low, and the preparation success rate is high; an electrotransfection instrument is used for electrotransfection, and compared with a traditional transfection mode, the repeatability is good, reagent cost is avoided, and the electrotransfection rate is high; the RNA vaccine is used for electrotransfecting the DC cell, compared with other biological treatment drugs, in-vitro production and purification are easy, and the production process is high in universality and high in safety; and the DC cell and the T cell which are subjected to electrotransfection are co-incubated and amplified, and the obtained activated vaccine is high in proportion and strong in immunogenicity.

The invention discloses a biosensing device for enhancing antigen and antibody binding optical detection signals, and the device comprises an adjusting box, wherein a first working box and a second working box are arranged at the top of the adjusting box; by arranging the heating piece, the material box and the metal plate, a solution pump in the material box pumps a solution for reaction into the reaction cavity, a good liquid environment is provided for reaction of antibodies and antigens, regular replacement can be achieved, the activity of liquid is kept, the metal plate is fixed to the bottom in the reaction cavity, and the metal plate is good in material biological compatibility; therefore, the good environment is provided for the antibody-antigen reaction, and the heating sheet can heat the interior of the reaction chamber so as to increase the temperature to the temperature beneficial to the enzyme reaction so as to promote the antibody-antigen reaction; the adjusting box, the second sliding block and the first sliding block are arranged, so the reflection receiving plate and the light emitter can slide at the bottom of the adjusting box at a constant speed, and constant-speed scanning is achieved.

The invention relates to a method for identifying a Mycobacterium species, comprising the steps of: a) contacting at least one immuno-cross reactive antigen component of a mycobacterial species with a sample of a body fluid of a human or animal individual; b) contacting at least one antibody, which is capable of reacting with a mycobacterial antigen, with said body fluid sample; c) detecting the presence of antigen-antibody complexes, and identifying the Mycobacterium species present in said body fluid sample.

The present disclosure relates generally to antibodies reactive with tumor-specific neoantigens, as well as neoantigen-binding fragments thereof. The present disclosure also relates to nucleic acids, expression cassettes, and expression vectors encoding the antibodies and neoantigen-binding fragments. The antibodies and neoantigen binding-fragments are useful for diagnosis and treatment of cancer.

An object of the invention is to provide a modified T-cell receptor (TCR) which does not cause the antigen responsiveness and which is capable of holding CD3 subunits on a cell membrane and causing the CD3 subunits to function. The invention is an invention related to a modified TCR comprising a first polypeptide and a second polypeptide, wherein the first polypeptide is a polypeptide which comprises a constant region of human TCRα or a fragment of the constant region and which does not comprise a variable region of human TCRα, and the second polypeptide is a polypeptide which comprises a constant region of human TCRβ or a fragment of the constant region and which does not comprise a variable region of human TCRβ.